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ABSTRACT
Cancer is currently one of the leading causes of mortality and morbidity worldwide.
Most anticancer therapies rely on small molecule drugs (<0.5 kDa). As with all small
molecule drugs, chemotherapy is highly toxic and presents many off-target side
effects. Peptide drugs offer improved specificity and are cheaper and more accessible
to manufacture. In this study, we have developed a support vector machine (SVM)
model in order to detect peptide sequences with potential anticancer activity through
scanning the Red Sea Metagenomic library. Furthermore, we conducted an in silico
study in order to analyze one of the peptides returned by the SVM pipeline and
assessed its cytotoxicity and the mode of cell death by conducting MTT and Annexin
V staining assays, respectively. We observed that the selected anticancer peptide
contains the C-terminal portion of the homeodomain structure, of human Pax6, an
antennapedia homeodomain region, and can bind DNA. Furthermore, we observed
dose-response cytotoxicity of HepG2 cells with our peptide. No such cytotoxicity
was observed in HeLa cells; a morphological change, however, was observed. We
examined the cytotoxicity of our drug against 1BR-hTERT normal skin cells. Our
peptide drug induced dose-dependent cytotoxicity that was markedly weaker than
that of cancer treated cells. Together our data illustrates the isolation of one peptide
drug candidate from the AUC Red Sea metagenomic library; furthermore, we were
able to observe the selective dose-dependent reduction of HepG2 cell viability
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INTRODUCTION

1) Literature Review
Cancer is currently one of the leading causes of mortality and morbidity
worldwide. In 2012, about 8 million deaths occurred around the world due to cancer,
and about 14 million new cases appeared; the number of new cancer cases per year
has been expected to rise by about 70% over the next two decades [1]. Cancer is a
term given to a collection of diseases characterized by uncontrolled cell division. The
abnormal tumor cells, which arise from normal cells, are able to grow anywhere in
the body and can arise from any tissue or cell type. As opposed to benign tumors,
malignant tumors (also known as cancers) can spread throughout the body and invade
any type of tissue far from the site of the original tumor. The cancer cells use blood
vessels and lymph vessels to travel around the body. In contrast to normal cells,
cancer cells are undifferentiated; that is, they may not carry out the same specific
functions as the original normal tissue cells. Moreover, cancer cells are desensitized
to the external chemical signals that regulate their growth, division, and functions.
Cancer cells are also able to influence their microenvironment; for example, a cancer
mass can influence the development of blood vessels, a process known as
angiogenesis, in order to provide itself with nutrients and waste removal. One of the
functions of the immune system is removal of the body’s aging and/or aberrant cells;
cancer cells however, have evolved mechanisms by which they can evade removal
by the immune system. Cancer arises through genetic changes in the normal cell (the
process of carcinogenesis); those changes can fall within one or a combination of
three main classes of genes: proto-oncogenes, tumor suppressors, or DNA repair
genes. Proto-oncogenes and tumor suppressor genes are responsible for ensuring
normal cell development, growth, and division while DNA repair genes are
specialized in repairing any mutations that can arise in the cell’s DNA. Mutations to
proto-oncogenes and tumor suppressors may occur due to exposure to mutagenic
agents such as radiation; failure to repair these mutations by the DNA repair
machinery results in the persistence of these mutations and subsequently results in
carcinogenesis. As is the case with the other genes, mutations to the DNA repair
genes can also develop through environmental stimuli or through aging [2, 3].
5

The currently used regiments for treating cancer remain problematic. The
foremost problem with conventional chemotherapy is the failure to administer the
correct amount of the chemotherapeutic agent directly and selectively to the tumor
mass or tissue. As a result, the treatment itself may become toxic to the patient.
Furthermore, several drug resistance mechanisms have been reported. Once the
chemotherapeutic agents have been transported into the cell, intracellular transport
mechanisms may re-route the chemotherapeutic agents back out of the cell before
they could interact with their intracellular targets. Clearly, there is a need for more
selective, more potent, and less toxic cancer therapeutics [4-6].
Towards the latter part of the 20th century, new classes of cancer therapeutics have
come into existence (namely, protein-based therapeutics) due to the advancements in
biotechnological techniques of that time (such as recombinant protein expression and
enhanced protein purification and analysis protocols). These new protein-based
therapeutics, or “biologics”, offer several advantages over the “small-molecule”
drugs: very high selectivity towards their targets, fewer side effects, and subsequently
higher potency. Examples of currently used biologics therapeutics include insulin,
growth factors, and engineered antibodies [6]. Biologics, however are tedious and
expensive to manufacture [6].
Small peptide drugs combine the best of both worlds: they possess the hallmark
potency and specificity of biologics, but are much smaller in size, more accessible,
and much cheaper to manufacture [6].
Among the classes of peptide drugs, are anticancer peptides [6]. Anticancer
peptides are small (5 to 50 amino acids), cationic, amphiphilic peptides [4-6]. The
major feature of anticancer peptides that dictates their specificity towards cancer cells
is their cationic net charge. In contrast to the normal cells, cancer cells have a
relatively negative charge; this relative negative charge is a result of the overexpression of anionic cell surface molecules such as phosphatidylserine, Oglycosylated mucins, siasilated ganglioside, and heparan sulfates [5, 7]. The
anticancer peptides are therefore, attracted to the membrane of cancer cells merely
6

through simple electrostatic interactions. However, membrane fluidity and
cholesterol content also affect the accessibility of the peptide into the cell [8].
Two main modes of action have been described for anticancer peptides:
membranolytic and non-membranolytic (Figure 1). Anticancer peptides acting
through the membranolytic mechanisms disrupt either the cell membrane,
mitochondrial membrane, or lysosomal membrane. The anticancer peptides can
disrupt the plasma membrane by either the carpet or barrel stave models. In the carpet
model, the cationic anticancer peptides align parallel to the cell membrane, and once

Figure 1: 3D representation of the major modes of action described for known
anticancer peptides so far. Mechanisms of action fall broadly into 2 categories:
Those which are membranolytic (left half-cell) and those which are nonmembranolytic (right half- cell). The membranolytic modes of action affect the
membranes of the cell, lysosome, or mitochondria (1, 2, 3, respectively). The nonmembranolytic modes of action either modify gene expression of pro-survival genes
and induce cell cycle arrest, or affect activity of calcium ion channels and proteasome
(4, 5, 6).
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a certain threshold concentration of the peptide is reached, the peptides can permeate
the plasma membrane. In contrast, anticancer peptides can aggregate, by hydrophobic
interactions, to form a structure through the plasma membrane resembling a
traditional ion channel. Anticancer peptides can also pass through the plasma
membrane and permeate the mitochondrial membrane where they will induce
swelling of the mitochondria and release of cytochrome c. Release of cytochrome c
can subsequently activate caspase 9 and 3. Furthermore, modification of the
lysosomal membrane by anticancer peptides can result in acidification of the cytosol.
The non-membranolytic mechanisms of action include activation of calcium
channels resulting in calcium ion influx, augmentation of proteasome activity,
inhibition of pro-survival genes, or cell cycle arrest [5, 9].
The HPRP-A2 peptide, described by Zhao et. Al. [10], has been found to rapidly
induce cytotoxicity in two gastric cancer cell lines by means of cellular membrane
destruction (Table 1). They described a combined mechanism by which the HPRPA2 peptide induces a rise in the intracellular levels of reactive oxygen species and the
depolarization of the mitochondrial membrane, which is indicative of mitochondrial
damage. The peptide was also able to result in cell cycle arrest. Furthermore, the
HPRP-A2 peptide resulted in increased cytotoxicity when used in combination with
chemotherapy. In contrast, the Kahalides can trigger modification of the lysosomal
membrane which results in cell death [9, 11]. The Kahalides come from an alga,
Bryopsis, that the saltwater marine mollusk, Elysia rufescens feeds on; Kahalide has
undergone phase II clinical trials against solid tumors [12]. Melittin is another
anticancer peptide; it has been described to induce apoptosis in HepG2 cells by
calcium ion influx through the activation of Ca2+/Calmodulin dependent protein
kinase [13]. Other peptides have been described to act in a combination of different
modes of action encompassing, in some cases such as Magainin, most of the known
mechanisms [9].
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Table 1: Mode of action of some representative anti-cancer peptides.
Peptide name
HPRP-A2

Kahalide
Melittin
Magainin

Mechanism of action
Cell membrane
desaturation
Mitochondrial
membrane destruction
Cell cycle arrest
Lysosomal membrane
modification
Calcium ion influx
Mainly membrane
destruction
Other modes of action
described

Publication
Zhao et. Al., 2015

Hamann and Otto, 1996
Wang et. Al., 2009
Mulder et. Al. 2013

2) Objectives
In this study, we attempt to construct a support vector machine (SVM) pipeline
that can detect peptide sequences with potential anticancer activity. We also select
the best candidate from the list of potential anticancer peptides and attempt to further
examine its potential anticancer activity through protein structure prediction,
modelling, visualization, and ligand binding prediction. We Also provide in vitro
evidence of the anticancer effect of our peptide.

9

MATERIALS AND METHODS

1) Computational Modeling
A. METAGENOMIC LIBRARY SCREENING AND CANDIDATE
PEPTIDE SELECTION
We adapted the method proposed by Tyagi et. Al. 2013 [14] for mining large
datasets containing potential anticancer peptide sequences in order to search the AUC
Metagenomic library. We compared a dataset of experimentally validated anticancer
peptides [15-19] to a dataset of antimicrobial peptides and another dataset of random
peptides.
All possible oligopeptide frequencies were investigated in a size range of 1 to 30
amino acids. We also calculated the amino acid and dipeptide (2 amino acids)
frequencies for the anticancer and antimicrobial datasets. We compared the
frequencies of amino acids and dipeptides in the anticancer and antimicrobial peptide
datasets to those of the peptides in the Metagenomic library (t-test, P<0.05,
Bonferroni multiple testing correction). Only the peptides recognized as anticancer
were chosen. A sliding window of increasing size, starting from 5 amino acids, was
used to generate the peptides from the Metagenomic library translated reads. The
recognized peptides were scored according to how well they conform to the mean
amino acid and dipeptide frequencies of the experimentally proven anticancer
dataset, that is, they fall within the standard error from the mean.
We searched the passing peptides for presence of Hidden Markov Models
(HMM’s) [20, 21] previously reported on experimentally verified anticancer
peptides.
We confirmed our final predictions using the online tool developed by Tyagi et al
[14] (http://crdd.osdd.net/raghava/anticp/).
B. FILTERING A SINGLE CANDIDATE FOR MODELLING
We selected a single anticancer peptide from the final shortlist of potential
anticancer peptides for modelling. The criteria used were cationicity, model
prediction score, and size.
10

C. PEPTIDE PERFORMANCE OPTIMIZATION
In order to increase the statistical performance of our peptide, when run against a
dataset of experimentally validated and random peptides, we carried out a series of
optimization steps. We ran the peptide sequence as a FASTA file on the AntiCP web
server for anticancer peptide prediction. We chose model 2 for analysis, which
compares the query to a set of experimentally validated anticancer peptides and
random peptides, as opposed to a dataset of anticancer and antimicrobial peptides.
Amino acid modifications were serially introduced to the peptide in order to
maximize the prediction score. We chose only the modifications that occurred outside
of the HMM alignment region. We stopped serial modifications as soon as the
prediction model returned a score high enough to differentiate the query as an
anticancer peptide.
D. BLASTp ALIGNMENTS
Using our peptide as a query against two datasets, we ran a BLASTp search using
default parameters, except for the threshold cutoff of 1000, since the sequence is
short. One dataset was downloaded from the APD2 web server containing all the
experimentally validated antimicrobial/ anticancer peptides [15]; the second
BLASTp search was against the NCBI database across Homo sapiens using all
default parameters in order to test for sequence similarity with human proteins.
E. 3D MODELLING
In order to proceed with the 3D modelling for our peptide, we ran our peptide
through I-TASSER, a web server for protein secondary structure prediction [22]. We
submitted the query peptide sequence as a FASTA file. Finally, we downloaded ITASSER output files for modelling and analysis.
We used the modelling and visualization software Chimera, developed by UCSF
in order to produce all modelling and visualization figures and numbers [23]. The
.pdb files from the protein sequence analysis and for the functional domains of the
two most similar proteins predicted by I-TASSER were fed into Chimera and we
conducted a series of alignments. We first superimposed all of the sequences using
default parameters in the MatchMaker tool within Chimera. We then conducted the
structural alignments in Chimera.
11

F. LIGAND AND BINDING SITE PREDICTION
We conducted ligand and binding site prediction using the web server COACH
for ligand prediction [24]. This web server predicts the possible ligands for a query
sequence and returns the most likely binding sites and binding site amino acids based
on the BioLip database [25]. The .pdb output files were downloaded and we fed them
into the Chimera software for protein-ligand visualization and analysis.
G. GENE EXPRESSION ANALYSIS
We used the R statistical programming software in order to investigate the
expression patterns of Pax6 and Meis2 (the closest transcription factors to our
peptides). We constructed several loops towards this end. We first started by calling
on the cgdsr and RCurl libraries within R. We then used the RCurl library to log into
The Cancer Genome Atlas (TCGA) link containing only the TCGA study data.
Initially, we looked at Pax6 and Meis2 expression data in general across all TCGA
studies. We constructed a loop that obtains the TCGA mRNA sequencing median zscores. The loop then computes the mean expression scores and deposits the results
in a matrix. A box plot was generated from within R to present the results.
Subsequently, we wanted to get a more detailed look at the expression data for
Pax6 and Meis2 in each cancer study. We constructed another loop to build a matrix
to hold the expression data for the gene of interest in each individual study. We called
on second generation RNA sequencing median z-scores in this loop. We Only
included the studies containing fully analyzed data. A bar plot was generated from
within R to present the data.
Finally, we were interested in studying the differential expression patterns of Pax6
and Meis2 between normal and cancer cells. We obtained level 3 RNA sequencing
data (normalized number of reads) for 15 cancer samples with their paired normal
tissue from the TCGA data portal. We subsequently constructed a count matrix in R
by combining all normal and cancer expression data with their genes into one matrix.
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In order to examine differentially expressed genes, we used the EdgeR library. We
followed the same workflow pipeline proposed by the Edger User’s Guide for
comparing cancer versus matched normal RNA-sequencing data.

2) Laboratory Validation
A. DRUG SYNTHESIS AND PREPARATION
The peptide drug was synthesized by GL Biochem LTD, Shanghai, China and
shipped as a lyophilized powder. The peptide was synthesized at 98% purity. We
stored the lyophilized powder in the -20 freezer in a sealed vial away from light.
We prepared stock solutions of our drug by dissolving the powder in deionized
water at a concentration of 1 mg / ml. We stored the stock solutions in 1 ml Eppendorf
tubes split into 0.5 ml aliquots.
B. CELL CULTURE
We used HepG2 (high passage number), HeLa cells, and 1BR- hTERT cells in
this study. The HepG2 cells were previously purchased from Vacsera, Egypt; they
are a hepatocellular carcinoma cell line derived from a hepatocellular carcinoma of a
15-year-old Caucasian male [26]. HeLa cells are a permanent human
adenocarcinoma cell line derived from a rare cervical adenocarcinoma of a 30-yearold black female [27, 28].The 1BR-hTERT cell line is an immortalized human skin
fibroblast cell line. Both the HeLa and 1BR-hTERT cells were kindly provided by
Dr. Andreas Kakarougkas.
We maintained the HepG2 cells in RPMI-1641 media (Lonza) completed with
10% heat inactivated fetal bovine serum (FBS) and 5% Penicillin-Streptomycin. The
HeLa cells were kept in DMEM (Lonza) completed with 10% heat inactivated FBS
and 5% Penicillin-Streptomycin. The 1BR-hTERT cells were kept in the same
conditions as the HeLa cells. We incubated the cell culture flasks at 37 degrees
Celsius with 5% CO2. We observed the cells under the Olympus 1X70 microscope
for morphology and cell death.
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C. CELL COUNT
In order to count cells for seeding, we used trypan blue staining. 20 µl of cells
were mixed thoroughly with 20 µl of trypan blue dye and the cells were counted
using a hemocytometer slide over 4 chambers. We calculated the number of cells
using the following formula:
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝑖𝑙𝑙𝑖𝑙𝑖𝑡𝑒𝑟 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ÷
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐ℎ𝑎𝑚𝑏𝑒𝑟𝑠 𝑢𝑠𝑒𝑑 𝑥 10,000

D. CELL CYTOTOXICITY ASSAY
We used the MTT assay in order to determine cell cytotoxicity after exposure to
the test condition. The MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
bromide) reagent is a yellow tetrazolium compound which reacts with the
mitochondrial dehydrogenase enzymes of viable cells. The reaction of the MTT
reagent with the dehydrogenase enzymes forms purple formazan crystals[29]. In
order to detect cell viability, as a measure of the cell cytotoxicity, after exposure to
the test conditions, we seeded HepG2 or HeLa cells in a 96- well plate (Corning,
USA) at a density of 1 x 104 cells in 100 µl of fresh complete media. After 24 hours
from seeding, we discarded the old media and added the peptide drug at
concentrations of 512, 256, 128, 64, 32, and 16 µg / ml diluted in fresh media by
serial dilutions. 24 hours following addition of the drug, we replaced the old media
with fresh media containing 0.5 mg/ml MTT (5mg/ml stock) (Serva, Germany) to
each well. We incubated the plate for 3 hours. We then discarded all the media and
added 100 µl of DMSO (Sigma-Aldrich, USA) to each well in order to dissolve the
formazan crystals. We incubated the plate at room temperature, wrapped in
Aluminum foil for 15 minutes. We measured absorbance at 490 nm using the BMG
Labtech Spectrostar Nano plate reader.
We calculated cell viability by subtracting the blank absorbance reading from all
other wells. We then divided the sample absorbance reading by the control
absorbance reading then multiplied by 100.
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For all experiments, we used several control conditions as follows: blank (media
with no cells), cells with complete media only, and cells with media and the solvent
used to prepare the drugs employed in the study. The solvent control was prepared
only for the highest drug concentration (i.e. as if preparing the 512 µg/ml but with no
drug). We subsequently converted mass volumes to molar volumes.
E. CELL DEATH ASSAY
We used the AlexaFlour 488 AnnexinV/ Dead Cell kit from ThermoFischer
Scientific in order to evaluate the mode of cell death in the treated cells. During the
highly regulated and programmed mode of cell death (apoptosis), the apoptotic cells
present phosphatidyl serine (PS) on the outer leaflet of their plasma membranes.
Annexin V, a human anticoagulant and phospholipid binding protein can readily bind
PS presented on the outside of the apoptotic cells. When conjugated with a
fluorophore, Annexin V can emit green light when excited with ultraviolet light.
Moreover, propidium iodide (PI) is a fluorophore that can tightly bind nucleic acids.
Live and apoptotic cells are impermeable to PI. PI, however, can permeate into dead
cells and bind their nucleic acids. When excited with ultraviolet light, PI emits red
light [30, 31].
We plated 0.3x106 HepG2 cells per well in a 6- well plate. We plated wells for
untreated control and drug treated (15.2 µM) conditions in duplicate. After 24 hours
we discarded the spent media and added the peptide drug to the treatment wells. After
another 24 hours we collected the media containing the floating cells and deposited
them in a 15ml falcon tube. We subsequently trypsinised the adherent cells and
combined those cells with the dead cells in the same falcon tube. We then pelleted
the cells by centrifugation for 5 minutes at 500 RCF 4 degrees Celsius. The
supernatant was discarded and the cells were re-suspended in 1 ml fresh media. 20 µl
of the cell suspension was used for counting. We then collected the appropriate
amount of cell suspension in order to obtain 50,000 cells. We pelleted this suspension
and washed with 100 µl PBS. Again, we pelleted the cells and re-suspended in 1x
Annexin binding buffer. We added 2 µl of the Annexin V reagent to the cell
suspension in addition to 1 µl of PI. We incubated the cells suspension in the dark for
15

15 minutes at room temperature. 25 µl of the resulting cell suspension was then
transferred to a glass slide and a cover slip was carefully placed over the droplet. We
visualized the cells under the microscope using the appropriate FITC filters.

3) Statistical Analysis
In order to calculate mean viability readings and standard deviation, we used the
raw un-blanked absorbance readings as input to the R statistical analysis software.
We trimmed the unused wells out of the absorbance readings table and blanked all
the absorbance readings. We also calculated the mean viability for each treatment.
We used the GraphPad Prism software to calculate the half maximal drug response
values (EC50) and to draw the dose response curves. We entered the raw viability data
for each set of replicates in each experimental condition along with the different
concentrations used. After the drug concentrations were log transformed and the data
normalized, we calculated the EC50 values. Furthermore, we tested the data for
normality and subsequently carried out either parametric or non-parametric two- way
ANOVA with multiple comparisons in order to obtain significance values for the
viabilities across the different drug concentrations.
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RESULTS

1) A predicted 37-residue anticancer
peptide
We screened the AUC Metagenomic library across translated sequences for
potential anticancer peptides. We obtained a list of 59 potential anticancer peptides,
in terms of anticancer versus antimicrobial and anticancer versus random peptide
scoring performance. While applying the filtering methods described, any anionic
peptides were disregarded and any peptides with a size larger than 50 amino acids
were also disregarded (since most anticancer peptides are cationic and fall within the
size range between 5 – 50 amino acids, roughly [5, 6]); two candidate peptides
remained. Both peptides contained HMM alignment profiles indicating presence of a
homeodomain (PF00046.). One peptide was 30 residues long while the other was 37.
We chose the 37 residue peptide, even though the shorter peptide was more cationic
since the homeodomain HMM occurred on residue 0 to 30 on the shorter peptide;
this would present a problem when optimizing the peptide since any mutations
introduced would likely influence the HMM alignment. This 37-mer peptide came
from the Atlantis II Deep brine pool sub-seafloor sediment section 6; the original
sequence of which can be found on the NCBI Short Sequence Archive (SRA) under
the name of the American University in Cairo along with the entire American
University in Cairo Red Sea Metagenomic Library. The original peptide sequence
was TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVMLTSI (Table 2). The
modified and optimized peptide sequence contains 3 Cysteins at positions 33, 34, and
36 in place of the original amino acids. The optimization of the original peptide
resulted in an increase in the model performance score; furthermore, the
hydropathicity of the peptide increased (Table 3).
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Table 2: Anticacancer Peptide Drug Information.
Nature of Data
Dataset
SVM Score
Peptide length
HMM id
HMM accession
HMM start
HMM end
ACP/AMP model prediction (Tyagi,
Atul, et al. 2013)
ACP/NON-ACP model prediction
(Tyagi, Atul, et al. 2013)
Hydrophobicity
Hydropathicity
Hydrophilicity
Charge
Molecular weight

Data
ATII-6Sediments_qc-prot.acp
3
37
Homeobox
PF00046.24
1
31
0.74
-0.98
-0.18
-0.39
0
4
4334.71

Table 3: The new chemical properties of the modified anticancer peptide
ACP/NON
-ACP
model
prediction
(Tyagi,
Atul, et al.
2013)
Original
-0.98
Modified
0.28

Hydropho
bicity

-0.18
-0.2

Hydropath Hydrophili
icity
city

-0.39
-0.34

0
-0.01

Charge

4
4

2) The predicted anticancer peptide is a
homeodomain protein that aligns with an
Arthropod defensin
We ran the chosen peptide sequence through a BLASTp search against two
datasets; one contained a list of experimentally validated anticancer/random peptides
from the AntiCP web server; the second dataset contained a list of experimentally
validated anticancer peptides from the APD2 peptide library. For the AntiCP dataset,
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our peptide aligned best with an anticancer/ anti-Gram+ peptide from Drosophila
virilis [32] (coverage= 24%, identity = 56%, E-value = 7.1) . The results for the
second alignment yielded an alignment with an Arthropod defensin from Stomoxys
calcitrans (the stable fly) [33] (coverage = 72%, identity = 33%, E-value = 9). We
submitted this peptide to the AntiCP server anticancer peptide prediction tool and it
predicted that this peptide is also an anticancer peptide; We also ran this sequence as
a query on the PFAM web tool and it confirmed that this sequence is that of an
arthropod defensin.
We ran our peptide through a third BLASTp search. This instance, however, we
ran our peptide against the NCBI non-redundant (nr) database and included only
Homo sapiens in the search. The best alignment was with the human homeobox gene
Six2 (E-value = 0.012) (Figure 2).

Figure 2: Summary of the best alignment returned by BLASTp against our
peptide.

3) The peptide contains a helix turn helix
structure and is structurally similar to
Pax6
In preparation for modeling and visualization of the predicted anticancer peptide,
we submitted the peptide sequence to I-TASSER, a web server for protein secondary
structure prediction. I-TASSER results indicated that our peptide consisted,
structurally, of two helices separated by a coiled region (C-score = -0.17); the two
helices lay roughly perpendicular (about 79 degrees) to one another, in accordance
to the consensus geometry of the homeodomain[34] (Figure 3). The protein
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structurally closest to our peptide is the homeodomain of the human paired box
protein, Pax6 (TM-score = 0.815, RMSD = 1.39, coverage = 1.000) (Figure 4).

Figure 3: 3D rendering of our peptide drug with two alpha helices forming an
angle of about 79 degrees.

Figure 4: Top 10 structurally closest proteins to our peptide as predicted by
TM-align tool within I-TASSER. We choose the second best structure
(structure arranged in descending order) since the first structure does not cover
the entire length of the sequence.
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As a confirmatory step, we obtained the homeodomain structure of Meis2 (one of
the proteins used by I-TASSER as a template to build our peptide structure, also a
human homeodomain protein) (Figure 5) protein and Pax6 and subsequently fed them
into Chimera with our peptide and we carried out two alignments: our peptide against
Pax6 and our peptide against Meis2. Our peptide aligned, in terms of sequence
(within 5 angstroms across all residues), with Meis2 at 42.42% identity across nongap stretches. On the other hand, Pax6 aligned with our peptide at only 13.5% identity
across non-gap stretches.

Figure 5: Top 10 templates used by I-TASSER to build the structure of our
peptide. We chose the second best template (Meis2 – results are arranged in
descending rank order) since it is a human protein, as opposed to PBX (the best
alignment) since it is a mouse protein.

The Pax6 homeodomain structure, however, was the closest to our peptide with a
plane angle between the planes of the C-terminal recognition helix and the two short
N-terminal helices of 78.3 degrees (figure 6b), as opposed to 79 degrees in our
peptide (figure 6a); Meis2 plane angles, however, were less congruent with our
peptide, at 62.3 degrees (Figure 6c).
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Figure 6: Plane angles formed between the recognition helices and N-terminal
helices of: A- our peptide, B- Pax6, and C- Meis2. The planes themselves simply
indicate the plane formed by each helix for ease of viewing.

4) Our peptide binds DNA over the same
sequences as the antennapedia
homeodomain
We wanted to find out the potential ligands for our peptide; therefore, we
submitted the structure file of our peptide (output by I-TASSER), to the ligand
prediction software, COACH. The most significant result was the output from the
COFACTOR tool within COACH. Our peptide was shown to bind nucleic acids, with
residues 5, 20, 24, 27, 28, 31 forming the binding site (C-score = 0.1). The closest
protein-nucleic acid set used by COACH prediction as a template for ligand
predication was from the Antennapedia homeodomain structure bound to DNA (PDB
9antA, TM-score = 0.767, RMSD = 0.81, coverage = 0.919). Using this model, we
were able to infer the DNA sequence to which our peptide would most likely interact:
5’-AGAAAGCCATTAGAG-3’

(Figure

7).

This

sequence

homeodomain- specific recognition sequence 5’-ATTA-3’.
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contains

the

Figure 7: 3D representation of our peptide (turqoise) aligned with
the Antennapedia homeodomain. The C-terminal recognition helix
is aligned with the major groove of the DNA molecule in the same
orientation as its template indicating sequence- specific interaction
potential.
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5) Pax6 andMeis2 expression patterns
across several cancers over TCGA
studies
Upon analyzing the expression data for Pax6 and Meis2, which we compiled from
TCGA, we observed that Pax6, on average, displays weak underexpression patterns
in the TCGA studies. We also observed that Meis2 shows a much more pronounced
average underexpression across the TCGA studies, on average (Figure 8).

Figure 8: Average gene expression patterns for Pax6 and Meis2.

When taking a closer look (Figure 9), we observed that Pax6 was overexpressed
in breast and liver tissue, while being underexpressed in cervical tissue. Meis2, in
contrast, was downregulated in breast and cervical tissue, while being upregulated in
liver tissue.
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Figure 9: Expression levels for Pax6 and Meis2 in select cancer types
representing the cell lines most widely used in our laboratory.

We were also interested in confirming the differential expression patterns of Pax6
and Meis2 in Liver Hepatocellular Carcinoma, represented by the HepG2 cell line in
our laboratory.
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Figure 10: Sample dispersion according to patterns of gene expression for
all genes in each HCC sample. The axes represent the leading log of fold
change. The samples for the cancer tissue red, blue, and orange circles) appeared
more dispersed and heterogeneous indicating varying expression levels. The
paired normal tissue samples (green circle) were tightly grouped and more
homogenous, indicating consistent expression patterns.

We examined the data obtained and observed, as expected, that the normal
samples were more homogeneous and tightly grouped than the tumor samples (Figure
10). The cancer samples were clustered chiefly into 3 major groups; we tried
searching in the patient data for a link between the clusters, however, we were not
able to find a clear link (Table 4).
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Table 4: Hepatocellular Carcinoma Patient Information
Cluster
Blue
Blue
Orange
Orange
Red
Orange
Blue
Red
Blue
Orange
Orange

Sample
Nr.
1
2
3
4
5
6
7
8
9
10
11

Case

Gender

Age

Stage

TCGA-BD-A3EP
TCGA-DD-A3A3
TCGA-DD-A3A4
TCGA-DD-A3A5
TCGA-DD-A3A6
TCGA-DD-A3A8
TCGA-EP-A3RK
TCGA-FV-A3I0
TCGA-FV-A3I1
TCGA-FV-A3R2
TCGA-G3-A3CH

Female
Male
Male
Female
Female
Male
Male
Female
Female
Male
Male

75
45
37
66
72
75
73
76
NA
75
53

I
I
IIIa
III
II
II
IIIa
II
II
I
IIIa

We observed that Pax6 and Meis2 were, indeed, expressed in liver hepatocellular
carcinoma; however, not differentially expressed (P<0.05) between normal and
tumor samples (Table 5).

Table 5: Differential Gene Expression Data for Pax6 and Meis2.
Genes
PAX6
MEIS2

log Fold Change
0.158089913
0.742735053
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PValue
0.716262029
0.171200501

6) Dose- dependent cytotoxicity upon
treatment of HepG2 cells.
We treated the HepG2 cells with our peptide at concentrations ranging from 512
to 3.7 µM. We noticed dose- dependent cytotoxicity with increasing drug dosage
(Figure 11). At the highest concentration, 121.5 µM, we obtained around 34%
viability. The viability gradually increased to about 73% for the lowest drug

Figure 11:Cytotoxicity drug response curve of HepG2 cells treated with our
peptide drug. Significance values are indicated relative to the control.
concentration of 3.8 µM. The concentrations which displayed statistically significant
results were 121.5 – 3.8 µM (P < 0.001). The EC50 for our peptide drug was calculated
to be about 8.6 µM.
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Upon examination of the drug treated HepG2 cells under the microscope, we
observed a vast morphological difference between control cells, and cells treated with
our peptide (Figure 12). Peptide-treated cells, however, looked enlarged, the cell

Figure 12: Morphological changes in HepG2 cells induced by our peptide
drug. A- Control cells incubated with media only; B- Cells treated with 121.5
µM of our peptide drug. The peptide drug treated cells, at the highest
concentration, appeared enlarged and had irregular shapes (rectangle) in
addition to a few cells with vacuoles indicated by the circles.
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surface looked rough, and the cells displayed multiple extensions. We also observed
a few vacuoles in the cells of the highest concentration. The morphological changes
gradually subsided with decreasing drug concentration.

7) Irregular cytotoxicity response of HeLa
cells to treatment with the peptide drug
In contrast to HepG2, Treatment of HeLa cells with our peptide (Figure 13) drug
did not elicit the same pronounced dose- response. At the highest concentration
(121.5 µM), our drug resulted in 73.5% viability; the lowest concentration (3.8 µM)
resulted in 87% viability. None of the treatment concentrations yielded statistically
significant differences in viability with a P- value below 0.001.

Figure 13: Cytotoxicity drug-response curve of HeLa cells treated with our
peptide drug.
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Upon examination of the drug treated cells under the microscope, we were able to
observe many vacuoles in the cells treated with the highest concentration (Figure 14).

Figure 14: Microscopy for HeLa cells treated with our peptide drug. Acontrol cells only with growth media; B- Cells treated with our peptide drug at
512 ug/ml. The treated cells were relatively morphologically different and
displayed many vacuoles (red circles).
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Some cells displayed irregular morphology as compared to the untreated control.

8) Cytotoxicity response of the 1BR-hTERT
cells incubated with the peptide drug
We observed a dose- dependent reduction in the viability of the 1BR-hTERT cells
upon treatment with increasing concentration of our drug (Figure 15). The highest
concentration yielded a viability of about 52%; the viability gradually increased to
approximately 88% at 15.2 µM, where the viability plateaued for the remaining
concentrations. The EC50 for the 1BR-hTERT cells was calculated to be
approximately 20.1 µM. The concentration of the drug used on the 1BR-hTERT cells
that was closest to the EC50 on HepG2 (7.6 µM) resulted in a non-significant drop in
viability as compared to the untreated control (that is, our peptide drug is not toxic to
normal cells at its HepG2 EC50)).

Figure 15: Cytotoxicity drug-response curve for 1BR-hTERT cells treated
with our peptide drug. All significance values were calculated relative to the
control. only the concentrations from 121.5 to 15.2 µM displayed significant
differences.

Upon examination of the cells under the microscope, we were able to observe a
slight morphological difference between the treated and untreated cells (Figure 16).
The treated cells at the highest concentration appeared irregular and shrunken. We
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Figure 16: Microscopy images of 1BR-hTERT cells treated with our peptide
drug. A- control cells with growth media only. B- cells treated with 121.5 µM
of drug. The cells treated with the highest concentration appeared to be smaller
and irregular in comparison to the control; those effects gradually subsided with
decreasing concentration.
observed that this morphology subsided gradually down to the 15.2 µM concentration
where the cells were only slightly smaller than the untreated cells.
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9) Increase in apoptotic activity upon
treatment of HepG2 cells with the
peptide drug
We qualitatively examined the mode of death for the HepG2 cells treated with the
peptide drug using ThermoFischer’s AlexaFlour488 Annexin V/ Dead Cell assay.
We observed a marked increase in apoptotic activity between treated and untreated
cells (Figure 17). Furthermore, we observed that the apoptotic cells from the drug
treated sample could be divided into two major groups: early and late apoptotic cells.
The early apoptotic cells appeared as bright green with faint or no red signal from PI
staining. The majority of the cells, however, were late apoptotic; these cells presented
as green-stained rings with a strong red signal in the center. We counted 1 early
apoptotic cell in the control from about 45 cells in bright field. In contrast, we counted
12 late apoptotic cells and 15 early apoptotic cells (with a total of 27 cells in bright
field) for the drug treated condition, in the microscope viewing field.
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Figure 17: Annexin V/ PI staining of HepG2 cells treated with our anticancer
peptide drug. Left column is the control, Right column is the drug treated cells. A,
B- bright field; C, D- Annexin staining (the arrows point to cells of late apoptosis
while the circles indicate early apoptotic cells; E, F- PI staining; G, H- combined
channels. These images indicate an increase in apoptotic activity in the drug treated
cells as opposed to the control.
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DISCUSSION
Peptide based therapeutics are currently gaining attention as a replacement, or at
least, a complement to small molecule therapeutics [4, 14, 35]. Large peptide drugs,
or biologics, circumvent the off target toxicity problem of small molecule drugs and
also offer much stronger action; that is, since biologics are more specific and ontarget, a much lower dose is needed to achieve the same effect. Biologics, however,
are expensive and tedious to produce. Small peptide drugs fall within the size gap
between small molecule drugs and biologics (0.5 to 5 kDa); they combine the small
size of small molecule drugs, and also the potency and specificity of biologics, while
also being relatively inexpensive and relatively less tedious to produce[4-6].
Small peptides with anticancer activity are cationic, amphiphilic, peptides
containing 5 to 50 amino acid residues. The cationic nature of those peptides confer
their specificity towards the relatively anionic cancer cells, in contrast to small
molecule chemotherapeutics while amphiphilicity aids in the plasma membrane
permeation [5].
We were able to develop a workflow for detecting potential anticancer peptide
sequences from the AUC Red Sea Metagenomic library using several support vector
machines (SVM’s). Our SVM pipeline was able to identify a list of possible
anticancer peptides from the AUC database. We filtered the resultant list of potential
anticancer peptides for the most promising candidate. Furthermore, we optimized our
peptide sequence in order to improve its performance in the SVM model. We believe
that none of the peptides were initially recognized as anticancer in our model because
more variation between anticancer and random peptide sequences was needed for the
model to recognize the peptide as being anticancer (i.e. a larger sample size with more
diverse sequences). The first SVM model (anticancer versus antimicrobial) was able
to identify the anticancer peptides right away since we were comparing two different
classes of small peptides. That is, comparing two different classes of proteins is easier
in terms of SVM models as opposed to comparing a peptide to all other peptides.
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We subsequently set out to gather some information about our peptide. We
conducted a few BLASTp alignments on NCBI. The most significant searches
suggested that the peptide aligns with an arthropod defensin and a human
homeodomain protein, Meis2. These results suggest that our peptide may also
possess some antimicrobial properties. Furthermore, the BLASTp results indicated
that the peptide might potentially have transcriptional regulatory activity within the
tumor cell; these results were confirmed by the HMM alignment which also indicated
that the peptide is, in fact, a DNA binding homeodomain peptide.
Secondary peptide structure prediction using I-TASSER combined with
visualization and modelling using Chimera confirmed the presence of the DNAbinding region of the homeodomain structure. The peptide contains two alpha helices
separated by a coiled region. The size-asymmetric helices lay at an almost
perpendicular angle to one another; a feature typical to homeodomain proteins[34].
Our peptide, however, lacks a third N-terminal short helix; put together, we
concluded that our peptide contains only the C-terminal DNA binding portion of the
homeodomain.
Ligand prediction and modelling using COACH and Chimera confirmed the DNA
binding activity of our peptide. We observed that the longer C-terminal helix does
the actual peptide-DNA interaction. The closest template model used for ligand
prediction by COACH was that of an Antennapedia homeodomain bound to DNA.
When we observed that our peptide might possibly have a transcriptional regulatory
mode of action we were concerned that it may not be able to localize inside the
nucleus where it exerts its effect. The observation, however, that our peptide aligns
with the antennapedia homeodomain sequence was reassuring since some research
indicates that portion of the antennapedia homeodomain can be used as a nuclear
localization signal in order to direct cell-penetrating peptides into the nucleus[36, 37].
In addition, we observed that our peptide is able to bind to DNA at the same sequence
as the Antennapedia homeodomain.
Based on the computational results, we initially hypothesized that our peptide will
probably either competitively bind to the Pax6 or Meis2 target promoter sequences
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and inhibit their effect or it will replace the action of inactive or mutated Pax6 or
Meis2. However, since our peptide was able to elicit dose-dependent cytotoxicity in
HepG2 cells and induce morphological changes in HeLa cells (two cancers with
opposing expression patterns of Pax6 and Meis2), we refuted this scenario. We
currently hypothesize that our peptide drug may be acting through one of the
membranolytic modes of action; namely, the mitochondrial mediated apoptosis
pathway. In order to confirm this hypothesis, it would be advisable to investigate the
levels of active caspase 9 and 3 and oligomerized Apaf-1 since they are indicative of
the mitochondrial mediated apoptotic pathway [5].
We also observed that the solvent in the 1BR-hTERT experiment did result in a
significant drop in cell viability (P<0.001). We attribute this discrepancy to their
being less growth medium available for the cells at the highest concentration (since
the solvent control was prepared at the highest concentration) where the solution was
about 50% deionized water and 50% media. This effect subsided once the drug
concentration (and subsequently the amount of deionized water) decreased. There
was, however, some degree of cell death that can be attributed to the drug since there
was a significant difference (P<0.001) in viability between the highest concentration
(121.5 µM) and the solvent control. This solvent “shadow” effect may be
circumvented by preparing a more concentrated stock solution; for example, 2 mg/ml
instead of 1 mg/ml. As for the HepG2 cells, we did not observe a significant
difference (P<0.001) in viability between the untreated control and the solvent
control, while there was a significant difference (P<0.001) between the highest
concentration (121.5 µM) and the solvent control.
Even though the results for HeLa treatment with our peptide drug did not yield
any reliable dose response curve, we were in fact able to observe morphological
differences between treated and untreated cells. The cells treated with 121.5 µM
displayed numerous large vacuoles indicative of cellular distress. It would be of
importance to try more time points for the treatment and observe if increasing
treatment duration would result in a dose response to the peptide drug treatment.
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In this study, we were able to construct an SVM model in order to sift through the
AUC Red Sea Metagenomic library and identify potential anticancer peptides. Out
of a list of about 59 potential hits, we were able to isolate one peptide using
cationicity, length, and model performance score as the main criteria. We were also
able to optimize this peptide for better model performance. 3D modelling and
sequence/ structure alignments provided insight into the potential action of the
selected peptide. Even though we were not able to clearly propose a distinct
mechanism of action for our peptide, we were able to observe a dose- dependent
cytotoxicity upon treatment with our peptide. In addition, we observed that our
peptide displayed less toxicity towards normal cells than cancer cells. The
performance and selectivity of our peptide can be augmented by introducing more
mutations into the amino acid sequence. More in-depth experimentation is needed,
however, in order to outline a more pronounced hypothesis regarding the mechanism
of action of our peptide drug. The activity of caspases 3 and 9 along with Apaf-1 need
to be examined. Furthermore, investigation of the mitochondrial potential may prove
beneficial in order to investigate whether the peptide drug is directly disrupting the
mitochondria. Our peptide drug may also be tested in combination with
chemotherapeutic agents in the hope that the additive effect of both agents would
lower the required dosage of each and reach a point of very low toxicity to normal
cells. Towards evaluating toxicity, further testing would be required in order to shed
light on levels of hemolytic activity of our peptide drug. There still remains much
research to be carried out in the field of cancer therapeutics. The need for more
specific, more potent, and less toxic therapeutics is higher than ever due to the
increasing global cancer burden.
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peptides with potential anticancer / antimicrobial activity on a large scale in metagenomic
datasets, illustrated on Red Sea metagenomics library (generated by AUC & KAUST and made
public at NCBI SRA) in his master thesis.
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